Patents by Inventor Tanweer Khan
Tanweer Khan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210071133Abstract: The present invention relates generally to growth of bacteria. More specifically the invention relates to a method for oxidative environment adaptation of anaerobic microorganisms and their use in developing new probiotics. In particular, the present invention provides a method for adaptation of anaerobic microorganisms and selection of more oxygen tolerant anaerobic microorganisms, said method comprising the steps of culturing said microorganisms with a stepwise dual induction of oxidative stress via applied voltage and oxygen diffusion, and a stepwise change of anti-oxidant/oxidized counterpart concentration ratio to adjust the redox state. New strains are also provided.Type: ApplicationFiled: November 18, 2020Publication date: March 11, 2021Inventors: Muhammad-Tanweer Khan, Fredrik Backhed
-
Publication number: 20200405777Abstract: The present invention relates generally to medicine. More specifically the invention relates to the use of synergistic probiotic bacteria as intervention for health. In particular, the present invention provides a strain of Faecalibacterium prausnitzii and a bacterial strain which has one or more of the characteristics of: (i) being acetate producing, (ii) being lactate consuming and (iii) having the ability to be an electron acceptor, for use in the treatment or prevention of a disease associated with reduced butyrate levels or a disease associated with reduced or low numbers of Faecalibacterium prausnitzii bacteria.Type: ApplicationFiled: October 28, 2016Publication date: December 31, 2020Inventors: Muhammad-Tanweer Khan, Fredrik Backhed
-
Patent number: 10876092Abstract: The present invention relates generally to growth of bacteria. More specifically the invention relates to a method for oxidative environment adaptation of anaerobic microorganisms and their use in developing new probiotics. In particular, the present invention provides a method for adaptation of anaerobic microorganisms and selection of more oxygen tolerant anaerobic microorganisms, said method comprising the steps of culturing said microorganisms with a stepwise dual induction of oxidative stress via applied voltage and oxygen diffusion, and a stepwise change of anti-oxidant/oxidized counterpart concentration ratio to adjust the redox state. New strains are also provided.Type: GrantFiled: October 28, 2016Date of Patent: December 29, 2020Assignee: METABOGEN ABInventors: Muhammad-Tanweer Khan, Fredrik Backhed
-
Publication number: 20200261421Abstract: The present invention is directed to compounds of Formula I, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.Type: ApplicationFiled: December 19, 2017Publication date: August 20, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Brian McKittrick, John P. Caldwell, John A. McCauley, Henry Vaccaro, Tin-Yau Chan, Hyunjin Kim, Elizabeth Smith, Liwu Hong, Tanweer Khan, Shihong Ying, Hongwu Wang
-
Publication number: 20200230140Abstract: The present invention provides methods of treating malaria comprising administration of an N3-substituted iminopyrimidinone of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables R1, R2, R3, R4, R5, A, B, L, m, and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: February 13, 2017Publication date: July 23, 2020Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical ResearchInventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs
-
Publication number: 20200223220Abstract: The present invention provides methods of treating malaria by administration of a compound of Formula (I): or a pharmaceutically acceptable salt of said compound, to a subject in need thereof, wherein the variables X, R1, R3, R4, R5, A, B, L, m and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: March 24, 2020Publication date: July 16, 2020Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical ResearchInventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs
-
Patent number: 10696639Abstract: The present invention is directed to compounds of Formula (I), pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.Type: GrantFiled: December 1, 2017Date of Patent: June 30, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Tanweer Khan, Elizabeth Smith, Peter Williams, Catherine Wiscount, Brian McKittrick, John McCauley
-
Publication number: 20200069691Abstract: The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.Type: ApplicationFiled: December 19, 2017Publication date: March 5, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Brian McKittrick, John P. Caldwell, John McCauley, Henry Vaccaro, Tin-Yau Chan, Hyunjin Kim, Elizabeth Smith, Liwu Hong, Tanweer Khan, Shihong Ying, Hongwu Wang, Peter D. Williams, Jae-Hun Kim, M. Brad Nolt, Maryann Caplen
-
Publication number: 20190382716Abstract: The present invention relates generally to growth of bacteria. More specifically the invention relates to a method for oxidative environment adaptation of anaerobic microorganisms and their use in developing new probiotics. In particular, the present invention provides a method for adaptation of anaerobic microorganisms and selection of more oxygen tolerant anaerobic microorganisms, said method comprising the steps of culturing said microorganisms with a stepwise dual induction of oxidative stress via applied voltage and oxygen diffusion, and a stepwise change of anti-oxidant/oxidized counterpart concentration ratio to adjust the redox state. New strains are also provided.Type: ApplicationFiled: October 28, 2016Publication date: December 19, 2019Inventors: Muhammad-Tanweer Khan, Fredrik Backhed
-
Publication number: 20190337902Abstract: The present invention is directed to compounds of Formula (I), pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.Type: ApplicationFiled: December 1, 2017Publication date: November 7, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Tanweer Khan, Elizabeth Smith, Peter Williams, Catherine Wiscount, Brian McKittrick, John McCauley
-
Publication number: 20190046507Abstract: The present invention provides methods of treating malaria by administration of a compound of Formula (I): or a pharmaceutically acceptable salt of said compound, to a subject in need thereof, wherein the variables X, R1, R3, R4, R5, A, B, L, m and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: February 13, 2017Publication date: February 14, 2019Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical ResearchInventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs
-
Patent number: 10138212Abstract: The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist.Type: GrantFiled: February 1, 2016Date of Patent: November 27, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Rongze Kuang, Yeon-Hee Lim, Michael Man-Chu Lo, Pauline C. Ting, Purakkattle Biju, Manuel de Lera Ruiz, Sylvia J. Degrado, Alexander L. Tung, Timothy J. Henderson, Liwu Hong, Jae-Hun Kim, Dong Won-Shik Kim, Joe Lee, Jie Wu, Heping Wu, Yushi Xiao, Tao Yu, Gang Zhou, Xiaohong Zhu, Kevin D. McCormick, Jayaram R. Tagat, Dong Xiao, Tanweer Khan, Jianhua Cao, Michael Berlin, Yonglian Zhang
-
Publication number: 20180207165Abstract: The invention relates to supporting the growth or maintenance of oxygen-sensitive bacteria in the gastrointestinal tract of an animal. Provided is the use of riboflavin, riboflavin phosphate or a salt thereof, for the manufacture of a food composition, pharmaceutical composition, food or dietary supplement, for the selective stimulation of Faecalibacterium prausnitzii in the gastrointestinal tract. Also provided is a synbiotic composition comprising living beneficial butyrate-producing anaerobic bacteria formulated with riboflavin, riboflavin phosphate or a salt thereof, and cysteine.Type: ApplicationFiled: March 9, 2018Publication date: July 26, 2018Inventors: Hermanus Josef Martinus Harmsen, Muhammad Tanweer Khan, Mehdi Sadaghian Sadabad, Jan Maarten Van Dijl
-
Publication number: 20180037554Abstract: The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist.Type: ApplicationFiled: February 1, 2016Publication date: February 8, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Rongze Kuang, Yeon-Hee Lim, Michael Man-Chu Lo, Pauline C. Ting, Purakkattle Biju, Manuel de Lera Ruiz, Sylvia J. Degrado, Alexander L. Tung, Timothy J. Henderson, Liwu Hong, Jae-Hun Kim, Dong Won-Shik Kim, Joe Lee, Jie Wu, Heping Wu, Yushi Xiao, Tao Yu, Gang Zhou, Xiaohong Zhu, Kevin D. McCormick, Jayaram R. Tagat, Dong Xiao, Tanweer Khan, Jianhua Cao, Michael Berlin, Yonglian Zhang
-
Patent number: 9428476Abstract: In its many embodiments, the present invention provides provides certain S-imino-S-oxo iminothiadiazine compounds, including compounds Formula (I): or a tautomers and/or stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein RN, R1, R2, R3, R4, ring A, RA, m, L1, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and may be useful for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.Type: GrantFiled: March 11, 2014Date of Patent: August 30, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Tanweer A. Khan, Jack D. Scott, Jared N. Cumming
-
Patent number: 9422255Abstract: In its many embodiments, the present invention provides certain S-imino-S-oxo iminothiazine compounds, including compounds Formula (I): or a tautomers and/or stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein RN, R1A, R1B, R2, R3, R4, ring A, RA, m, L1-, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and may be useful for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.Type: GrantFiled: March 11, 2014Date of Patent: August 23, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Tanweer A. Khan, Jack D. Scott, Jared N. Cumming
-
Publication number: 20160016923Abstract: In its many embodiments, the present invention provides certain S-imino-S-oxo iminothiadiazine compounds, including compounds Formula (I): or a tautomers and/or stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein RN, R1, R2, R3, R4, ring A, RA, m, L1, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and may be useful for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.Type: ApplicationFiled: March 11, 2014Publication date: January 21, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Tanweer A. Khan, Jack D. Scott, Jared N. Cumming
-
Publication number: 20160016921Abstract: In its many embodiments, the present invention provides certain S-imino-S-oxo iminothiazine compounds, including compounds Formula (I): or a tautomers and/or stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein RN, R1A, R1B, R2, R3, R4, ring A, RA, m, L1-, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and may be useful for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.Type: ApplicationFiled: March 11, 2014Publication date: January 21, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Tanweer A. Khan, Jack D. Scott, Jared N. Cumming
-
Publication number: 20160000838Abstract: The present invention relates to medicine, particularly immunology and gastroenterology. Specifically, it relates to probiotic bacteria and extracts thereof for therapeutic use for the treatment of inflammatory disorders such as inflammatory bowel disease. Provided is a composition comprising as active ingredient Faecalibacterium prausnitzii strain HTF-F (DSM 26943) or an extract thereof comprising extracellular polymeric matrix (EPM), and an acceptable carrier, diluent or excipient. Also provided is an anti-inflammatory composition comprising EPM extracted from F. prausnitzii strain HTF-F, and a method for preparing the same.Type: ApplicationFiled: March 5, 2014Publication date: January 7, 2016Applicants: RIJKSUNIVERSITEIT GRONINGEN, THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, WAGENINGEN UNIVERSITEIT, ACADEMISCH ZIEKENHUIS GRONINGENInventors: Hermanus Josef Martinus HARMSEN, Muhammad Tanweer KHAN, Jeremy WELLS, Oriana ROSSI, Harry James FLINT, Sylvia Helen DUNCAN
-
Patent number: 9156848Abstract: The present invention is directed to novel substituted dihydropyrrolopyrazoles of structural Formula I which are inhibitors of the dipeptidyl peptidase-N enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase IV enzyme is involved.Type: GrantFiled: July 18, 2013Date of Patent: October 13, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Tesfaye Biftu, Tanweer A. Khan